First study of BA1202 for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the informed consent form approved by the ethics board and follow study rules
- You have an advanced or metastatic solid tumor that has progressed on standard treatment, or you can’t tolerate standard treatment, or there is no standard option
- If you are in the colorectal, lung (non-small cell), pancreatic, or stomach cancer group, your tumor must have high CEACAM5 (at least 20% of tumor cells with IHC 2+ or 3+)
- You have at least 1 scan-visible lesion that doctors can measure (for the eligible group) and you expect to live at least 3 months
- Blood tests must meet key levels: low infection risk (neutrophils), enough platelets, and enough hemoglobin; and liver/kidney and blood clotting tests must be within allowed ranges
- You must not have had certain cancer treatments too recently and must not have had prior CEA-targeting treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.